None

Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX dose groups. Aditxt, Inc. (NASDAQ: ADTX) jumped 113.8% to close at $0.37. Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA) surged 101% to close at $3.86 after a late Monday Form 4 filing showed multiple insider purchases of the stock. NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) climbed 79.3% to close at $29.90 on Tuesday as the stock started trading on a 1-for-30 reverse split basis. 89bio, Inc. (NASDAQ: ETNB) shares rose 40% to close at $7.00. Analysts reportedly said Akero's NASH data could be a positive for the company's Pegoza program in NASH. Motorsport Games Inc. (NASDAQ: MSGM) climbed 28.1% to close at $0.97. Motorsport Games, last month, reported worse-than-expected Q2 EPS results. Akouos, Inc. (NASDAQ: AKUS) gained 28% to close at $4.48. The FDA has signed off Akouos Investigational New Drug application to initiate a Phase 1/2 trial of AK-OTOF, gene therapy for otoferlin gene (OTOF)-mediated hearing loss. Infobird Co., Ltd (NASDAQ: IFBD) jumped 28% to settle at $2.47. Golden Path Acquisition Corporation (NASDAQ: GPCO) rose 22.4% to settle at $8.69. Ensysce Biosciences, Inc. (NASDAQ: ENSC) gained 22.3% to close at $0.4131. Immuneering Corporation (NASDAQ: IMRX) jumped 22.1% to close at $12.00. Immuneering recently submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its product candidate IMM-1-104 in development for the treatment of advanced RAS mutant solid tumors. Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) rose 21% to close at $0.2299. VNET Group, Inc. (NASDAQ: VNET) gained 20.7% to close at $5.66 after the company announced the receipt of a preliminary non-binding proposal to acquire all of its shares and formation of a special committee to review the proposal. Cosmos Holdings Inc. (NASDAQ: COSM) climbed 19.7% to settle at $0.4216. Cosmos Health’s subsidiary SkyPharm recently launched its first Sky Premium Life products on Amazon in the U.S. Palisade Bio, Inc. (NASDAQ: PALI) jumped 18.3% to settle at $0.1782. Palisade Bio was Granted U.S. patent titled 'Administration of serine protease inhibitors to the stomach.' Aprea Therapeutics, Inc. (NASDAQ: APRE) gained 17.7% to close at $0.9299. Phunware, Inc. (NASDAQ: PHUN) surged 15.6% to settle at $1.63. NLS Pharmaceutics AG (NASDAQ: NLSP) gained 14.2% to close at $1.12. Laidlaw & Co. recently initiated coverage on NLS Pharmaceutics with a Buy rating and announced a price target of $6. iBio, Inc. (NYSE: IBIO) rose 13.7% to close at $0.3080 after declining over 4% on Monday. Planet Labs PBC (NYSE: PL) gained 13.5% to close at $6.15 after the company reported better-than-expected Q2 results and raised guidance. Aehr Test Systems (NASDAQ: AEHR) gained 13.5% to close at $15.99 ...

Related tickers: JSPR, CVNA, APP, AKUS, IBIO, LMDX, TYME, AAPL, PYPD, VNET, TRDA, RCKT, AEHR, RLAY, ASAN, SLNH, SYNH, AMZN, NLSP, U, KPRX, HUT, COIN, MSGM, KC, BRZE, RUBY, CROX, PALI, NCRA, PHUN, HLVX, PTON, MSFT, TUEM, UPST, CMRA, CDAK, MSTR, VTAQ, NRBO, VVX, AKRO, NVDA, EWTX, APRE, MEGL, BBIO, PLCE, IFBD, W, ETNB, RENT, WKME, INM, VERO, CTV, ENSC, BNTC, ZNTL, LXU, CNM, HKD, CRDF, PL, IMRX, SYRS, HYMC, PACB, BOXD, COSM, ADTX, REAL, GPCO.

Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 176.5% to close at $31.00 on Thursday after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to shareholders. Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) gained 51% to settle at $27.03 after the FDA Advisory Committee voted that available evidence of effectiveness is sufficient to support approval of AMX0035 for the treatment of ALS. Citigroup and SVB Leerink raised their price targets. Rubius Therapeutics, Inc. (NASDAQ: RUBY) climbed 48.6% to close at $1.29 after declining 11% on Wednesday. Rubius Therapeutics, last month, posted a Q2 loss of $0.49 per share. Benitec Biopharma Inc. (NASDAQ: BNTC) shares gained 33% to close at $0.7880. The company, last week, filed its annual report on Form 10-K for the quarter ended June 30, 2022, with the U.S. Securities and Exchange Commission. Marker Therapeutics, Inc. (NASDAQ: MRKR) rose 31.5% to close at $0.3999 after the company's Phase 2 study of multi-tumor-associated antigen-specific T cell therapy for relapsed/refractory AML appeared on the FDA's Orphan Products Grants Program site. Palatin Technologies, Inc. (NYSE: PTN) gained 26.2% to close at $6.31 after the company announced the initiation of patient recruitment for its Phase 2 study evaluating oral PL8177 in ulcerative colitis. LifeStance Health Group, Inc. (NASDAQ: LFST) jumped 25.8% to close at $9.57. LifeStance Health named Ken Burdick as CEO and Chairman. T Stamp Inc. (NASDAQ: IDAI) gained 25% to settle at $1.85. Asana, Inc. (NYSE: ASAN) shares gained 24.8% to close at $23.76 after the company reported better-than-expected results for its second quarter and issued a strong sales guidance. RBC Capital and Citigroup raised their price targets on the stock. Relay Therapeutics, Inc. (NASDAQ: RLAY) gained 23.8% to close at $31.37. Relay Therapeutics announced efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients with a FGFR2-fusion or rearrangement FGFR inhibitor-naïve cholangiocarcinoma: ReFocus trial. Revance Therapeutics, Inc. (NASDAQ: RVNC) gained 21.6% to close at $25.30 after the company announced FDA approval of DAXXIFY for injection for temporary improvement of moderate to severe frown lines. SPAR Group, Inc. (NASDAQ: SGRP) rose 21.3% to close at $1.54 after the company's board of directors initiated a process to evaluate potential strategic alternatives including a sale, merger or other strategic transaction. Allarity Therapeutics, Inc. (NASDAQ: ALLR) rose 20.4% to settle at $1.30. Eve Holding, Inc. (NYSE: EVEX) jumped 20% to close at $7.39. United reported a $15 million investment in Eve Air Mobility and a conditional purchase agreement for 200 four-seat electric aircraft plus 200 options. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) climbed 18.9% to settle at $708.85 after the company announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema and wet age-related macular degeneration. Eyenovia, Inc. (NASDAQ: EYEN) gained 18.6% to close at $2.48. VistaGen Therapeutics, Inc. (NASDAQ: VTGN) jumped 18.4% to close at $0.1953 after the company announced the completion of an interim analysis of its PALISADE-2 Phase 3 ...

Related tickers: LYFT, PTN, VERO, GNTA, ALLR, VTGN, TLF, GDYN, ASAN, EVEX, HLGN, NH, VHC, RLAY, FHS, ALLG, ALBO, AVAV, CRHC, SLVM, WLY, ATXG, GSAT, TERN, IDAI, NOGN, SNAP, MERC, IMCR, ANVS, SHPH, PIXY, REGN, TRKA, TNDM, AMLX, SGRP, LFST, RVNC, SABR, EYEN, SKIL, INTA, W, AGS, AEO, ENSC, RYTM, BILI, CTV, ERAS, PLAY, RUBY, GME, GPCO, AKA, LOVE, MKC, CZOO, BNTC, MRKR, PHR, PRCT, MCFT, ISEE, CEMI, RIVN, ZG, BPTS, GPL, MULN.